|
End-of-day quote
New Zealand S.E.
05/10/2026
|
5-day change | 1st Jan Change | ||
| 4.300 NZD | -1.60% |
|
-2.05% | +27.22% |
| 09-08 | Aft Pharmaceuticals Limited Partners with Mark Cuban Cost Plus Drug Company to Bring Combogesic to the U.S | CI |
| 07-31 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call |
| Market Cap | 451M 252M 225M 210M 191M 359M 24.31B 362M 2.53B 986M 12.41B 947M 927M 39.88B | P/E 2027 * |
22.9x | P/E 2028 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 481M 269M 240M 224M 204M 383M 25.91B 386M 2.7B 1.05B 13.23B 1.01B 988M 42.51B | EV / Sales 2027 * |
1.58x | EV / Sales 2028 * | 1.38x |
| Free-Float |
22.37% | Yield 2027 * |
0.76% | Yield 2028 * | 0.97% |
| Markets | Quality | ||
|---|---|---|---|
New Zealand S.E.
| AFT | End-of-day quote | |
Australian S.E.
| AFP | Delayed |
Last Transcript: AFT Pharmaceuticals Limited
| 20/01/24 | Rentevrees zet Bel20 onder druk | |
| 19/01/24 | KBC uitblinker op groene beurs | |
| 19/01/24 | Brusselse beurs opent flink hoger | |
| 19/01/24 | Brussel start handelsdag vermoedelijk in het groen | |
| 18/01/24 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | -1.60% | ||
| 1 week | -2.05% | ||
| 1 month | -1.60% | ||
| 3 months | +16.22% | ||
| 6 months | +27.98% | ||
| Current year | +27.22% |
| 1 week | 4.26 |  | 4.4 |
| 1 month | 4.2 | | 4.48 |
| Current year | 3.35 | | 4.85 |
| 1 year | 2.79 | | 4.85 |
| 3 years | 2.37 | | 4.85 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 04/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 04/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 15/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 22/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 04/09/1997 |
Marree Atkinson
BRD | Director/Board Member | - | 04/09/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/3/25 A | Buy | Founder | 200,000 | 0.1907% | ||
| 6/26/25 A | Free | Founder | 17,755 | 0.0169% | ||
| 12/2/24 A | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.60% | -2.05% | +54.12% | +29.13% | 257M | |
| +0.02% | -3.52% | +35.27% | +111.11% | 1,019B | |
| -1.21% | -6.99% | +34.42% | +60.96% | 617B | |
| +1.12% | -0.20% | +15.45% | +80.24% | 464B | |
| -3.30% | -6.15% | +57.14% | +34.69% | 356B | |
| +0.93% | -3.16% | +21.65% | +43.02% | 333B | |
| +0.12% | -2.77% | +10.70% | +32.97% | 267B | |
| -0.89% | -6.28% | -7.00% | +8.01% | 244B | |
| -0.01% | -2.81% | +35.28% | +51.82% | 218B | |
| -0.08% | -4.17% | +28.34% | +93.51% | 179B | |
| Average | -0.86% | -3.52% | +28.54% | +54.54% | 369.74B | |
| Weighted average by Cap. | -0.54% | -3.67% | +28.63% | +68.58% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 170M 152M 141M 129M 242M 16.38B 244M 1.71B 664M 8.36B 638M 625M 26.87B | 345M 193M 172M 161M 146M 275M 18.61B 277M 1.94B 755M 9.5B 725M 710M 30.53B |
| Net income | 19.7M 11.02M 9.83M 9.16M 8.34M 15.7M 1.06B 15.82M 111M 43.07M 542M 41.38M 40.49M 1.74B | 24.81M 13.89M 12.39M 11.54M 10.5M 19.78M 1.34B 19.93M 139M 54.26M 683M 52.13M 51.01M 2.19B |
| Net Debt | 29.84M 16.7M 14.9M 13.88M 12.63M 23.78M 1.61B 23.96M 168M 65.24M 821M 62.68M 61.33M 2.64B | 24.6M 13.77M 12.28M 11.44M 10.41M 19.61M 1.33B 19.75M 138M 53.79M 677M 51.68M 50.56M 2.17B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/10/26 | NZ$4.300 | -1.60% | 14,327 |
| 02/10/26 | NZ$4.370 | +1.16% | 9,913 |
| 01/10/26 | NZ$4.320 | +0.47% | 7,954 |
| 30/09/26 | NZ$4.300 | -0.92% | 23,427 |
| 29/09/26 | NZ$4.340 | -0.23% | 12,849 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
